Please login to the form below

Not currently logged in
Email:
Password:

rituximab

This page shows the latest rituximab news and features for those working in and with pharma, biotech and healthcare.

Roche’s diagnostic business sales offer a bright spot in Q4

Roche’s diagnostic business sales offer a bright spot in Q4

treatments Herceptin (trastuzumab), Avastin (bevacizumab) and Rituxan (rituximab).

Latest news

More from news
Approximately 9 fully matching, plus 151 partially matching documents found.

Latest Intelligence

  • Will biosimilars ever catch on in the US? Will biosimilars ever catch on in the US?

    The UK has been especially proactive with biosimilars. Three biologics there – infliximab, rituximab and etanercept –underwent an average price reduction of 40% when their biosimilars were introduced. ... After the launch of the biosimilar for

  • The sound of silence puts the squeeze on generics and biosimilars The sound of silence puts the squeeze on generics and biosimilars

    drugs - from Adalimumab to Rituximab - go off-patent and boost savings across eight European nations to 33.4bn over the next three years.

  • 2016: The year when deal-makers took stock? 2016: The year when deal-makers took stock?

    Canada for biosimilar versions of Rituxan (rituximab) and Herceptin (trastuzumab). .

  • Deal Watch December 2016 Deal Watch December 2016

    Sanofi's payments to JHL, the Taiwanese manufacturer of a rituximab biosimilar, total $101m upfront for the China market alone; 30% of the headline figure.

  • Deal Watch November 2016 Deal Watch November 2016

    By destroying B cells, rituximab is used to treat diseases characterised by excessive numbers of B cells, overactive B cells or dysfunctional B cells including many lymphomas, leukaemias, transplant rejection and ... In May this year Sandoz announced

More from intelligence
Approximately 0 fully matching, plus 10 partially matching documents found.

Latest appointments

  • ImmunoGen hires VP product strategy ImmunoGen hires VP product strategy

    His previous business experience includes several oncology-related positions at Biogen Idec, including team leader for Rituxan (rituximab), as well as commercial positions at Amgen,.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • Covid-19: how is it affecting prescribing patterns?

    From March 2019, use of on-patent Etanercept, Adalimumab and Rituximab went down, while the Adalimumab biosimilar went up and so did Etanercept and Rituximab biosimilars.  This is to be expected

  • The Biosimilar Challenge

    Herceptin, Avastin, Rituximab and Erbitux) and autoimmune disease (e.g. Humira, Enbrel, Remicade, MabThera and RoActemra to name a few).

  • Biosimilars: Getting the flock to market

    The greatest attraction, naturally, is high-revenue anti-TNF agents like MabThera (rituximab) and Humira (adalimumab), for many years the world's most valuable drug.

More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Page & Page and Partners

For those who can imagine better, Page & Page and Partners (P&P) is home to meaningful encounters of a marketing, communication...

Latest intelligence

01 PME-APR21 Cover.jpg
Virtual congresses: video thrilled the cardio tsar
Chris Ross explores the key learnings from a year of virtual congresses...
When Will We Be Back To Normal?
The definitive question of 2021, whether you’re a homeschooling parent, a homebound professional, a wanderer with nowhere to go… or all three at once....
How to tell your healthcare story.
Healthcare research is not a simple story and the people in charge of those moments need to be careful about the story that they tell....

Infographics